Education
About Us
Working with TipRanks
Follow Us
Protagenic Therapeutics (PTIX)
OTHER OTC:PTIX
Total Valuation
Protagenic Therapeutics has a market cap or net worth of $887.18K. The enterprise value is $1.89M.
Market Cap$887.18K
Enterprise Value$1.89M
Share Statistics
Protagenic Therapeutics has 1,810,208 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,810,208
Owned by Insiders―
Owned by Institutions3.52%
Financial Efficiency
Protagenic Therapeutics’s return on equity (ROE) is 1.10 and return on invested capital (ROIC) is 379.69%.
Return on Equity (ROE)1.10
Return on Assets (ROA)-2.42
Return on Invested Capital (ROIC)379.69%
Return on Capital Employed (ROCE)1.24
Revenue Per Employee0.00
Profits Per Employee-5.16M
Employee Count1
Asset Turnover0.00
Inventory Turnover35.12
Valuation Ratios
The current PE Ratio of Protagenic Therapeutics is ―. Protagenic Therapeutics’s PEG ratio is -0.00238.
PE Ratio―
PS Ratio0.00
PB Ratio-0.54
Price to Fair Value-0.54
Price to FCF-0.61
Price to Operating Cash Flow-0.23
PEG Ratio-0.00238
Income Statement
In the last 12 months, Protagenic Therapeutics had revenue of 0.00 and earned -5.16M in profits. Earnings per share was -3.45.
Revenue0.00
Gross Profit-37.72K
Operating Income-5.83M
Pretax Income-5.16M
Net Income-5.16M
EBITDA-8.02M
Earnings Per Share (EPS)-3.45
Cash Flow
In the last 12 months, operating cash flow was -4.14M and capital expenditures -3.00, giving a free cash flow of -4.14M billion.
Operating Cash Flow-4.14M
Free Cash Flow-4.14M
Free Cash Flow per Share-2.29
Dividends & Yields
Protagenic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.84
52-Week Price Change-86.72%
50-Day Moving Average0.55
200-Day Moving Average2.39
Relative Strength Index (RSI)49.76
Average Volume (3m)102.28K
Important Dates
Protagenic Therapeutics upcoming earnings date is Apr 1, 2024, Before Open (Confirmed).
Last Earnings DateNov 16, 2021
Next Earnings DateApr 1, 2024
Ex-Dividend Date―
Financial Position
Protagenic Therapeutics as a current ratio of 0.34, with Debt / Equity ratio of -67.27%
Current Ratio0.34
Quick Ratio0.34
Debt to Market Cap1.25
Net Debt to EBITDA-0.12
Interest Coverage Ratio-19.64
Taxes
In the past 12 months, Protagenic Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Protagenic Therapeutics EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.84.
EV to Sales0.00
EV to EBITDA-0.43
EV to Free Cash Flow-0.84
EV to Operating Cash Flow-0.84
Balance Sheet
Protagenic Therapeutics has $2.21M in cash and marketable securities with $3.16M in debt, giving a net cash position of -$943.26K billion.
Cash & Marketable Securities$2.21M
Total Debt$3.16M
Net Cash-$943.26K
Net Cash Per Share-$0.52
Tangible Book Value Per Share-$3.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Protagenic Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast64.85%